Mallinckrodt completes spin-off of Par Health and transitions to Keenova focused on branded therapeutics

Arthur Cox advised Mallinckrodt on the spin-off of its Par Health business and Mallinckrodt’s subsequent evolution to a company focused on branded therapeutics. The transaction involved the separation of Par Health, comprising Mallinckrodt’s generic pharmaceuticals and sterile injectables business, into a distinct business. As part of this corporate reorganisation, Mallinckrodt will reposition itself as Keenova, with a strategic focus on branded therapeutics. Arthur Cox represented Mallinckrodt with a team composed by: Stephen Ranalow (Partner, Corporate and M&A), Niamh O’Toole (Senior Associate, Corporate and M&A), Fintan Clancy (Partner, Tax), David Molloy (Partner, Debt Finance), Maeve Moran (Partner, Corporate and M&A), Olivia Mullooly (Partner, Intellectual Property) and Colin Kavanagh (Partner, Life Sciences).

Mallinckrodt completes spin-off of Par Health and transitions to Keenova focused on branded therapeutics

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads